Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis

BACKGROUND: Mechanistic biosimulation can be used in drug development to form testable hypotheses, develop predictions of efficacy before clinical trial results are available, and elucidate clinical response to therapy. However, there is a lack of tools to simultaneously (1) calibrate the prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Brian J, Casey, Fergal P, Paterson, Thomas, Chan, Jason R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717130/
https://www.ncbi.nlm.nih.gov/pubmed/23841912
http://dx.doi.org/10.1186/1471-2105-14-221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717130/
https://www.ncbi.nlm.nih.gov/pubmed/23841912
http://dx.doi.org/10.1186/1471-2105-14-221

Ejemplares similares